Genomic Assays and Adjuvant Therapy for HR+ Breast Cancer

Video

The value of utilizing a genomic test to help guide decisions for adjuvant therapy for HR-positive breast cancer.

CancerNetw_HRBreast_CC_Kal_Seg03_Adj
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      prostate cancer
      Diagnosis and Management of mCSPC
      The Oncotype DX Breast Recurrence Score for HR+ Breast Cancer
      The Oncotype DX Breast Recurrence Score for HR+ Breast Cancer
      Genomic Testing vs Genetic Testing for HR+ Breast Cancer
      Genomic Testing vs Genetic Testing for HR+ Breast Cancer
      Informed Decision-Making in HR+ Breast Cancer
      Informed Decision-Making in HR+ Breast Cancer
      Neoadjuvant Therapy for HR+ Breast Cancer
      Neoadjuvant Therapy for HR+ Breast Cancer
      NCCN Guidance on Gene Profiling in Early-Stage HR+ Breast Cancer
      NCCN Guidance on Gene Profiling in Early-Stage HR+ Breast Cancer
      Gene Profile-Directed Therapy for Early-Stage HR+ Breast Cancer
      Gene Profile-Directed Therapy for Early-Stage HR+ Breast Cancer
      The Oncotype DX Breast Recurrence Score: Clinical Trial Data
      The Oncotype DX Breast Recurrence Score: Clinical Trial Data
      Role of Gene Profiling Assays in Early-Stage HR+ Breast Cancer
      Role of Gene Profiling Assays in Early-Stage HR+ Breast Cancer
      Perioperative Decision-Making in HR+ Breast Cancer
      Perioperative Decision-Making in HR+ Breast Cancer
      Related Content
      Treatment Options in Metastatic Castration-Sensitive Prostate Cancer

      Treatment Options in Metastatic Castration-Sensitive Prostate Cancer

      ONCOLOGY Staff
      March 13th 2022
      Article

      In this program Atish D. Choudhury, MD, PhD, discusses recent updates on long-term safety and efficacy data in patients with metastatic castration-sensitive prostate cancer and the importance of patient communication and quality of life while on treatment.

      Treatment Considerations for PARP Inhibitors in First-Line Maintenance Therapy in Patients With Advanced Ovarian Cancer

      Treatment Considerations for PARP Inhibitors in First-Line Maintenance Therapy in Patients With Advanced Ovarian Cancer

      April 22nd 2021
      Article

      This article reviews emerging evidence on PARP inhibitors as first-line maintenance treatment options after chemotherapy and features expert insights from Rebecca Previs, MD.